Multi-stage delivery system

Information

  • Patent Grant
  • 10751478
  • Patent Number
    10,751,478
  • Date Filed
    Wednesday, October 4, 2017
    6 years ago
  • Date Issued
    Tuesday, August 25, 2020
    3 years ago
Abstract
A multi-stage drug delivery system having a cartridge and multiple plungers positioned in the cartridge and spaced apart from one another is provided. A first plunger, a second plunger, and the cartridge form a first chamber storing a first drug. The second plunger and the cartridge form a second chamber storing a second drug. A cannula pierces the first plunger to access the first drug. As the first plunger is driven toward the second plunger, the first drug is expelled from the first chamber for delivery to a patient through the cannula. After expelling the first liquid drug, the cannula can pierce the second plunger to access the second drug. As the first and second plungers are together driven toward a closed end of the cartridge, the second liquid drug is expelled from the second chamber for delivery to the patient through the cannula.
Description
TECHNICAL FIELD

Embodiments generally relate to medication delivery. More particularly, embodiments relate to drug delivery systems for delivering multiple different drugs.


BACKGROUND

Many patients may be required to receive dosages of different drugs. Conventional drug delivery systems, such as many conventional wearable drug delivery devices, typically only provide a dosage of a single drug. Therefore, a patient may be required to use multiple conventional drug delivery devices to receive the different drug dosages. With each additional device, the patient is required to insert a new needle to facilitate delivery of each drug. Accordingly, what is needed is a drug delivery system that can deliver multiple different drugs and dosages in a less burdensome manner while reducing patient discomfort.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 illustrates an exemplary multiple stage (multi-stage) drug delivery system.



FIG. 2 illustrates the multi-stage drug delivery system of FIG. 1 in a first stage of operation.



FIG. 3 illustrates the multi-stage drug delivery system of FIG. 1 in a second stage of operation.



FIG. 4 illustrates the multi-stage drug delivery system of FIG. 1 in a third stage of operation.



FIG. 5 illustrates the multi-stage drug delivery system of FIG. 1 in a fourth stage of operation.



FIG. 6 illustrates the multi-stage drug delivery system of FIG. 1 in a fifth stage of operation.



FIG. 7 illustrates the multi-stage drug delivery system of FIG. 1 in a sixth stage of operation.



FIG. 8 illustrates an exemplary method for delivering multiple liquid drugs to a patient.





DETAILED DESCRIPTION

This disclosure presents various systems, components, and methods related to a drug delivery system. Each of the systems, components, and methods disclosed herein provides one or more advantages over conventional systems, components, and methods.


Various embodiments provide a multiple stage (multi-stage) drug delivery system and method of use. The multi-stage drug delivery system can include two or more chambers for storing liquid drugs. The multi-stage drug delivery system can deliver each drug to a user in succession. The multi-stage drug delivery system can include the same drugs or different drugs. The multi-stage drug delivery system can store and dispense the same amount of each drug or different amounts of each drug. Each drug can be delivered at a desired rate over a desired amount of time. The multi-stage drug delivery system can interface with a variety of different fluid delivery mechanisms to pass the stored drugs to the user. The multi-stage drug delivery system provides a simplified architecture for storing and dispending multiple different drugs to the user within the same container, enabling the user to use a same needle insertion to deliver the drugs. The multi-stage drug delivery device can be implemented within an on-body or wearable drug delivery device. Other embodiments are disclosed and described.


Various embodiments include a multi-stage drug delivery system having a cartridge, a first plunger positioned in the cartridge, and a second plunger positioned in the cartridge with the second plunger spaced apart from the first cartridge. The first plunger can be accessible through a first end of the cartridge. The first plunger, the second plunger, and the cartridge can form a first chamber configured to store a first liquid drug. The second plunger and the cartridge can form a second chamber configured to store a second liquid drug. A cannula can pierce the first plunger to access the first liquid drug. As the first plunger is driven toward the second plunger, the first liquid drug can be expelled from the first chamber for delivery to a patient through the cannula. After expelling the first liquid drug, the cannula can pierce the second plunger to access the second liquid drug. As the first and second plungers are together driven toward a closed end of the cartridge, the second liquid drug can be expelled from the second chamber for delivery to the patient through the cannula. The multi-stage drug delivery system allows two or more drugs to be delivered to a patient at different predetermined times, in different amounts, and according to different rates.



FIG. 1 illustrates a multi-stage drug delivery system 100. The multi-stage drug delivery system 100 can include a cartridge 102, a first plunger 104, and a second plunger 106. The multi-stage drug delivery system 100 can further include a first drug 108 and a second drug 110. The first and second drugs 108 and 110 can be any therapeutic agent including liquid drugs. The first and second drugs 108 and 110 can be different therapeutic agents or drugs. The multi-stage drug delivery system 100 can separately store and dispense the first and second drugs 108 and 110 using a common or shared drug delivery mechanism while enabling each drug to be dispensed at different times according to different customized schedules (e.g., different rates of delivery). The cartridge 102 can be of any size or shape. As an example, the cartridge 102 can be cylindrical with a circular cross-sectional shape.


As shown in FIG. 1, the first drug 108 can be stored in a first chamber 114 defined by the first plunger 104, the second plunger 106, and the cartridge 102. The storage and use of the first drug 108 in the first chamber 114 can represent a first stage of the multi-stage drug delivery system 100. The second drug 110 can be stored in a second chamber 116 defined by the second plunger 106 and the cartridge 102. The storage and use of the second drug 110 in the second chamber 116 can represent a second stage of the multi-stage drug delivery system 100.


The first and second drugs 108 and 110 can be hermetically separated and sealed by the cartridge 102 and the first and second plungers 104 and 106 as shown in FIG. 1. The first and second plungers 104 and 106 can be elastomeric plungers. The first and second drugs 108 and 110 can be provided in a common device (e.g., the cartridge 102) while ensuring the first and second drugs 108 and 110 are separately stored and dispensed. The first and second plungers 104 and 106 can be positioned anywhere along an interior portion of the cartridge 102.


The multi-stage drug delivery system 100 can be used in a drug delivery device that provides the first and second drugs 108 and 110 to a user. For example, the multi-stage drug delivery system 100 can be part of a bolus device and/or a wearable drug delivery device. The multi-stage drug delivery system 100 can include the same or different amounts of the first and second drugs 108 and 110 (e.g., the dosages of the first and second drugs 108 and 110 can be the same or different). The first drug 108 can be dispensed first over a first amount of time at a first rate of delivery with the second drug 110 dispensed over a second amount of time at a second rate of delivery, after the first drug 108 is dispensed. The multi-stage drug delivery system 100 enables the first and second drugs 108 and 110 to be provided to the user using the same fluid path to the user. Consequently, a single needle insertion can be used to deliver the first and second drugs 108 and 110.


The multi-stage drug delivery system 100 can dispense the second drug 110 immediately after the first drug 108 has been dispensed or can deliver the second drug 110 after a delay. Accordingly, the first and second drugs 108 and 110 can be delivered relatively close together in time or can be delivered at separate times after a desired delay. Further, the delivery of the first and second drugs 108 and 110 can be customized in terms of the rate at which each drug is delivered. For example, the first drug 108 can be delivered over a first amount of time while the second drug can be delivered over a second, different amount of time. The first and second amounts of time can be varied as desired to dispense the first and second drugs 108 and 110 at different desired rates of delivery, respectively. In this way, a customized delivery of the first and second drugs 108 and 110 can be provided with the dosages (e.g., how much drug to dispense in total), delivery times (e.g., when to dispense a drug), and delivery schedules (e.g., how quickly or slowly to dispense the dosage) for each drug being largely independent of each another.



FIG. 1 shows the multi-stage drug delivery system 100 in an initial state. Specifically, no mechanical energy or force is introduced or applied to the multi-stage drug delivery system 100 as shown in FIG. 1. A cannula 112 is shown in relatively close proximity to the multi-stage drug delivery system 100. The cannula 112 can be a hard cannula 112 that is sterilized. The cannula 112 can be positioned adjacent to the cartridge 102 or within an open area of the cartridge 102 yet still displaced from the first plunger 104. The cannula 112 can initially be positioned entirely outside of the cartridge 102. FIG. 1 can represent the multi-stage drug delivery system 100 before activation (e.g., before activation of a wearable drug delivery device in which the multi-stage drug delivery system 100 operates).


As shown in FIG. 1, the cannula 112 can be positioned adjacent to a first end of the cartridge 102. In particular, the cannula 112 is positioned in proximity to a first surface 118 of the first plunger 104. The first surface 118 can be adjacent to an open end of the cartridge 102 which allows the cannula 112 to enter the cartridge 102. The first plunger 104 can further include a second surface 120. The second surface 120 can be adjacent to the first drug 108. The second plunger 106 can also include a first surface 122 and a second surface 124. The first surface 122 can be adjacent to the first drug 108 and the second surface 124 can be adjacent to the second drug 110 as shown.



FIG. 2 illustrates insertion of the cannula 112 into the first stage of the multi-stage drug delivery system 100 (e.g., into the first chamber 114). As shown in FIG. 2, indicator 202 indicates application of a force applied to the cannula 112. The application of the force 202 to the cannula 112 can cause the cannula 112 to pierce and pass through the first plunger 104. The force 202 can be such that the cannula 112 pierces through the first plunger 104 to enter the first stage (e.g., the first chamber 114) holding the first drug 108. The force 202 can cause the cannula to enter the first chamber 114 at a desired depth. For example, the cannula 112 can pierce the first plunger 104 and enter the first stage at a depth so as to maximize extraction of the first drug 108 stored in the first chamber 114. In various embodiments, the body of the first plunger 104 may be counter-bored to facilitate piercing by the cannula 112.


As shown in FIG. 2, to enter the first chamber 114 holding the first drug 108, the cannula 112 can be caused to pierce the first surface 118 and the second surface 120 of the first plunger 104 and to extend through the first plunger 104. A tip or end or the cannula 112 can be sharp or pointed to facilitate piercing of the first plunger 104. To obtain access to the first chamber 114, the cannula 112 can be caused to move in a lateral direction toward a far end of the cartridge 102 as shown. The tip or end of the cannula 112 can be positioned near to the second surface 120 of the first plunger 104 once access to the first chamber 114 is provided. The cannula 112 can be positioned at a center of the first plunger 104 but is not so limited. In various embodiments, the first plunger 114 can be inserted along any portion of the first surface 118 of the first plunger 104 for example.


Once the cannula 112 is inserted into the first stage of the multi-stage drug delivery system 100 at a desired depth, the first drug 108 can be introduced into the fluid delivery mechanism coupled to the cannula 112. As an example, the cannula 112 can be coupled to a fluid delivery mechanism that delivers the first drug 108 to a user or patient. A variety of fluid delivery mechanisms can be used. For example, the fluid delivery mechanism can include one or more components for coupling the cannula 112 to the patient. In various embodiments, the components can include tubing (e.g., plastic and/or stainless steel tubing) coupled to the cannula as well as a needle or cannula (e.g., coupled to the tubing) for accessing a site on the patient. Overall, the fluid delivery mechanism 198 can be or can provide a fluid path 178 from the cannula to the user of the multi-stage drug delivery system 100. Accordingly, when the cannula 112 is coupled to a liquid drug, then the fluid path can be used to deliver the liquid drug to the user. In various embodiments, the cannula 112 can be part of the fluid delivery mechanism 198 or can be coupled to it. In various embodiments, the cannula 112 can be coupled via the fluid path 178 to the patient.


The fluid delivery mechanism 198 can further be used to apply the force 202. As an example, the fluid delivery mechanism 198 can include a cannula insertion component 188 for driving the cannula 112 in a direction indicated by the applied force 202 to pierce the first plunger 104. The cannula insertion component 188 can be coupled to the cannula 112 and can be triggered to cause the cannula 112 to advance toward the first plunger 104 to pierce the first plunger 104. In various embodiments, the cannula insertion component 188 can comprise a mechanical system or an electromechanical system for manipulating the cannula 112. In various embodiments, the cannula insertion component 188 can include one or more springs such as, for example, an expansion spring, a compression spring, and/or a torsion spring. The cannula insertion component 188 can be triggered to pierce the cannula 112 through the first plunger 104 based on a user input or action that indicates a desire to activate delivery of the first drug 108 (e.g., by a user pressing a button on a wearable drug delivery device to activate the device).


Further, the fluid delivery mechanism 198 can include a drive component, such as 168, to apply a force 204 on the first plunger 104 to force the first drug 108 out of the first stage of the multi-stage drug delivery system 100. For example, after the cannula 112 pierces the first plunger 104 and is positioned at a desired depth within the first chamber 114, a second force can be applied to the first plunger 104 as indicated by indicators 204. The force 204 can be applied to any portion of the first surface 118 of the first plunger 104 (e.g., at one or more positions along the first surface 118). The force 204 can drive the first drug 108 out of the first chamber 114, through the fluid delivery mechanism 198 (e.g., the cannula 112 and any other components coupling the cannula to the patient), and on to the user. The force 204 can cause the first plunger 104 to move towards the stationary second plunger 106. The drive component 168 can be coupled to the first plunger 104. In various embodiments, the drive component 168 can comprise a mechanical system or an electromechanical system for driving the first plunger 104 toward the far end of the cartridge 102. In various embodiments, the drive component 168 can include one or more springs such as, for example, an expansion spring, a compression spring, and/or a torsion spring.


The applied force 204 can be constant or varied and can be used to deliver the first drug 108 to the user over a desired amount of time (e.g., at a desired rate of delivery). For example, a relatively strong force 204 can be applied to rapidly provide the first drug 108 to the user. Alternatively, a relatively weak force 204 can be applied to slowly provide the first drug 108 to the user. In general, any delivery schedule and rate of delivery of the first drug 108 can be provided by using and varying the force 204.



FIG. 2 also shows a stroke 206 of the multi-stage drug delivery system 100—that is, the distance the first plunger 104 travels to expel all or approximately all of the first drug 108 from the first chamber 114 of the multi-stage drug delivery system 100 (e.g., the stroke 206 can represent the amount of the first drug 108 that can be stored and provided to a user). As discussed above, the stroke 206 can be varied by the amount of the first drug 108 included in the multi-stage drug delivery system 100 and the magnitude and timing of the force 204 applied to the first plunger 104 can determine how the amount of the first drug 108 is provided to the user. FIG. 2 can represent a state of the multi-stage drug delivery system 100 when the first drug 108 is initially accessed (e.g., when the cannula 112 is first introduced into the first chamber 114). FIG. 2 can represent the multi-stage drug delivery system 100 after activation and as delivery of the first drug 108 to the user first begins.



FIG. 3 illustrates extraction of the first drug 108 from the multi-stage drug delivery system 100. Specifically, FIG. 3 shows the first plunger 104 being driven towards the second plunger 106. The second plunger 106 can be in a fixed position. As a result, the first drug 108 can be forced out of the first chamber 114 of the multi-stage drug delivery system 100, through the cannula 112, and on to the fluid delivery mechanism 198 coupled to the cannula 112 for delivery to the user. As shown in FIG. 3, indicator 302 represents the first liquid drug 108 from the first chamber 114 being expelled out of the first chamber 114 through the cannula 112. The first liquid drug 108 can flow out of the cartridge 102 in a direction that is substantially opposite to the direction of the movement of the first plunger 104 towards the second plunger 106 which causes the first liquid drug 108 to be expelled out of the first chamber 114.


As shown in FIG. 3, the force 204 can be applied to the first plunger 104 to drive it towards the second plunger 106. The inserted position of the cannula 112 can remain in relatively the same position with respect to the first plunger 104 to ensure maximize extraction of the first drug 108. A reduction in stroke 304 is also shown for reference in FIG. 3. The reduction in stroke 304 can indicate that the size of the first chamber 114 of the multi-stage drug delivery system 100 has been reduced and that a corresponding amount of the first drug 108 has exited the multi-stage drug delivery system 100 through the cannula 112 for delivery to the user. FIG. 3 can represent a state of the multi-stage drug delivery system 100 when the first drug 108 is being extracted.



FIG. 4 illustrates the multi-stage drug delivery system 100 after depletion of the first drug 108. That is, FIG. 4 shows the multi-stage drug delivery system 100 after all or approximately all of the first drug 108 has been extracted from the first chamber 114 of the multi-stage drug delivery system 100. As shown in FIG. 4, the first plunger 104 is in close proximity to the second plunger 106 (e.g., adjacent such that no portion of the first drug 108 remains between the first and second plungers 104 and 106). The second surface 120 of the first plunger 104 can be adjacent to or pressed against the first surface 122 of the second plunger 106.


The force 204 applied to the first plunger 104 can drive the first plunger 104 to the position shown in FIG. 4. As the first drug 108 is being depleted and as the first plunger 104 is forced against the second plunger 106, the cannula 112 can be introduced into the second plunger 106. As shown in FIG. 4, a portion of the end of the cannula 112 can pierce a portion of the second plunger 106. The cannula 112 can pierce the first surface 122 of the second plunger 106 and can be partially inserted into the second plunger 106. The state of the multi-stage drug delivery system 100 as shown in FIG. 4 can be a state following depletion of the first drug 108 and prior to extraction of the second drug 110.



FIG. 5 illustrates insertion of the cannula 112 through the second plunger 106 of the multi-stage drug delivery system 100 and into the second chamber 116. As shown in FIG. 5, a second force 502 can be applied to the cannula 112 to drive the cannula 112 through the second plunger 106. The end of the cannula 112 can extend into the second chamber 116 of the multi-stage drug delivery system 100 a desired amount to ensure maximum extraction of the second drug 110. The cannula 112 can extend beyond the second surface 124 of the second plunger to be coupled to the second liquid drug 110 stored in the second chamber 116.


When the cannula 112 is inserted through the second plunger 106 and into the second chamber 116 of the multi-stage drug delivery system 100, the second drug 110 can be introduced into the fluid path coupled to the user (e.g., a fluid path coupled to the cannula 112). Specifically, the second drug 110 can be provided to the delivery mechanism coupled to the cannula 112 so that the second drug 110 may be passed on to the user. As shown, the force 204 can be applied to the first plunger 104 to move both the first plunger 104 and the second plunger 106 toward the end of the cartridge 102. That is, by applying the force 204 to the first plunger 104, the second plunger 106 is forced to move toward an end of the cartridge 102. In turn, the volume or size of the second chamber 116 is reduced which forces the second drug 110 through the cannula 112 and on to the fluid delivery mechanism.



FIG. 5 also shows a stroke 504 for the second chamber 116 of the multi-stage drug delivery system 100—that is, the distance the second plunger 106 travels to expel all or approximately all of the second drug 110 from the second chamber 116 of the multi-stage drug delivery system 100 (e.g., the amount of the second drug 110 that can be stored and provided to a user). As discussed above, the stroke 504 can be varied by the amount of the second drug 110 included in the multi-stage drug delivery system 100 and the magnitude and timing of the force 204 applied to the first plunger 104 (and the second plunger 106) can determine how the amount of the second drug 110 is provided to the user. FIG. 5 can represent a state of the multi-stage drug delivery system 100 when the second drug 110 is initially accessed (e.g., when the cannula 112 is first introduced into the second chamber).



FIG. 6 illustrates extraction of the second drug 110 from the multi-stage drug delivery system 100. Specifically, FIG. 6 shows the first plunger 104 and the second plunger 106 together being driven toward the end of the cartridge 102. As a result, the second drug 110 can be forced out of the second chamber 116 of the multi-stage drug delivery system 100, through the cannula 112, and on to the fluid delivery mechanism coupled to the cannula 112 for delivery to the user. As shown in FIG. 6, the force 204 can be applied to the first plunger 104 (and to the second plunger 106 indirectly) to drive both the first and second plungers 104 and 106 towards the end of the cartridge 102. The inserted position of the cannula 112 can remain in relatively the same position with respect to the second plunger 106 to ensure maximize extraction of the second drug 110.


As shown in FIG. 6, indicator 602 represents the second liquid drug 110 from the second chamber 116 being expelled out of the second chamber 116 through the cannula 112. The second liquid drug 110 can flow out of the cartridge 102 in a direction that is substantially opposite to the direction of the movement of the first plunger 104 and the second plunger 106 towards the end of the cartridge 102 which causes the second liquid drug 110 to be expelled out of the second chamber 116.


A reduction in stroke 604 is also shown for reference in FIG. 6—for example, to indicate the second chamber 116 of the multi-stage drug delivery system 100 has been reduced and that a corresponding amount of the second drug 110 has exited the multi-stage drug delivery system 100 for delivery to the user.



FIG. 6 illustrates the multi-stage drug delivery system 100 in a state of delivering the second drug 110 to a user. That is, FIG. 6 can represent a state after the cannula 112 has pierced through the second plunger 106 and the second drug 110 is being delivered to the user but prior to all of the second drug 110 being extracted.


In various embodiments, the force 502 can generally be applied to drive the cannula 112 through the plungers 104 and 106. The force 502 can then be removed or stopped and the force 204 can be applied or reapplied to drive the first plunger 104 (and the second plunger 106 when appropriate) towards the end (e.g., a closed end) of the cartridge 102. That is, the force 502 may not be used to drive the plungers 104 and 106 to the end of the cartridge 102. The force 204 can be applied along any portion of the first plunger 104 (e.g., including one or more positions along any portion of the first plunger 104).



FIG. 7 illustrates the multi-stage drug delivery system 100 after depletion of the second drug 110. That is, FIG. 7 shows the multi-stage drug delivery system 100 after all or approximately all of the second drug 110 has been extracted from the second chamber 116 of the multi-stage drug delivery system 100. As shown in FIG. 7, the first and second plungers 104 and 106 are positioned against the end of the cartridge 102 (e.g., adjacent to the end of the cartridge 102 such that no portion of the second drug 108 remains between the second plunger 106 and the end of the cartridge 102).


As shown in FIG. 7, the second plunger 106 has met the end of stroke. Accordingly, the delivery of the dosage of the second drug 110 is substantially complete (e.g., all of the second drug 110 has been forced out of the second chamber 116). FIG. 7 can represent a state of the multi-stage drug delivery system 100 after both the first and second drugs 108 and 110 have been delivered to the user. The multi-stage drug delivery system 100 can be re-used (e.g., re-filled) or can be discarded.



FIGS. 1-7 illustrate the multi-stage drug delivery system 100 having two chambers (e.g., chambers 114 and 116) but is not so limited. That is, the multi-stage drug delivery system 100 can include any number of chambers (and corresponding number of plungers) to store and subsequently dispense any number of different drugs, in any amount, according to any desired delivery schedule in accordance with the techniques described herein. FIGS. 1-7 can represent cross-sectional side views of the multi-stage drug delivery system 100 during various stages of operation as described herein.



FIG. 8 illustrates a method 800 for delivering multiple liquid drugs to a patient using a multi-stage delivery system such as, for example, the multi-stage delivery system 100. The method 800 is described in relation to delivering two liquid drugs to the patient from the multi-stage delivery system but is not so limited. The method 800 is applicable to the delivery of any number of liquid drugs from a multi-stage delivery system configured to store a corresponding number of liquid drugs as will be appreciated by a person of ordinary skill in the art. Further, the method 800 is applicable to the delivery of different liquid drugs, to the delivery of different amounts of each liquid drug, and to the delivery of each liquid drug at different times and rates as will be appreciated by a person of ordinary skill in the art.


At 802, a container configured to store a first drug in a first chamber and configured to store a second drug in a second, different chamber can be provided. The first and second drugs can be liquid drugs. The first and second drugs can be any type of liquid drugs. The first and second liquid drugs can be the same or different drugs. The first and second chambers can be of the same size or can be configured to store different amounts of the first and second drugs, respectively.


The first and second drugs can be sealed and separated from each other. A first plunger positioned in the container, a second plunger positioned in the container and spaced apart from the first plunger, and the container can form the first chamber. The second plunger and the container can form the second chamber.


At 804, a cannula can pierce the first plunger. The cannula can be positioned at a center of the first plunger. The cannula can extend through the first plunger and into the first chamber. The cannula can extend into the first chamber by a desired amount or depth and can be coupled to the first drug.


The cannula can be coupled to the patient. Accordingly, when the cannula accesses the first drug stored in the first chamber the cannula can couple the first drug to the patient.


At 806, the first plunger is driven toward an end of the container. The first plunger is advanced further into the container toward the second plunger. The cannula can remain positioned in the first plunger as the first plunger is advanced. The second plunger can remain stationary. As a result of the first plunger moving further into the container, the first drug is expelled from the first chamber (e.g., as the size or volume of the first chamber is reduced). The expelled first drug can flow into and through the cannula and on to the patient.


The first plunger can be advanced to expel substantially all of the first drug. When substantially all of the first drug is expelled, the first plunger can be positioned against the second plunger.


At 808, the second plunger can be pierced by the cannula. The cannula can extend through the second plunger (and through the first plunger) and into the second chamber. The cannula can extend into the second chamber by a desired amount or depth and can be coupled to the second drug. Accordingly, when the cannula accesses the second drug stored in the second chamber the cannula can couple the second drug to the patient.


At 810, the first plunger and second plungers are driven toward the end of the container. The first and second plungers are advanced further into the container toward a closed end of the container. The cannula can remain positioned in the first and second plungers as the first and second plungers are advanced. As a result of the first and second plungers moving further into the container, the second drug is expelled from the second chamber (e.g., as the size or volume of the second chamber is reduced). The expelled second drug can flow into and through the cannula and on to the patient.


The first and second plungers can be advanced to expel substantially all of the second drug. When substantially all of the second drug is expelled, the second plunger can be positioned against the closed end of the container with the first plunger positioned against the second plunger.


The following examples pertain to additional further embodiments:


Example 1 is a multiple stage drug delivery system, comprising a cartridge, a first plunger positioned in the cartridge, and a second plunger positioned in the cartridge, wherein the first plunger, the second plunger, and the cartridge form a first chamber configured to store a first liquid drug, and the second plunger and the cartridge form a second chamber configured to store a second liquid drug.


Example 2 is an extension of Example 1 or any other example disclosed herein, further comprising a cannula configured to pierce the first plunger to access the first liquid drug stored in the first chamber.


Example 3 is an extension of Example 2 or any other example disclosed herein, further comprising a cannula insertion component coupled to the cannula.


Example 4 is an extension of Example 3 or any other example disclosed herein, wherein the cannula insertion component comprises one or more springs.


Example 5 is an extension of Example 3 or any other example disclosed herein, wherein the cannula is coupled to a patient, wherein the cannula couples the first liquid drug stored in the first chamber to the patient when the cannula accesses the first chamber.


Example 6 is an extension of Example 5 or any other example disclosed herein, further comprising a drive component configured to advance the first plunger toward the second plunger, thereby extracting the first liquid drug from the first chamber for delivery to the patient through the cannula.


Example 7 is an extension of Example 6 or any other example disclosed herein, wherein the drive component comprises one or more springs.


Example 8 is an extension of Example 6 or any other example disclosed herein, wherein the drive component comprises an electromechanical system.


Example 9 is an extension of Example 6 or any other example disclosed herein, wherein the cannula is configured to pierce the second plunger to access the second liquid drug stored in the second chamber after the first liquid drug is extracted from the first chamber.


Example 10 is an extension of Example 9 or any other example disclosed herein, wherein the cannula couples the second liquid drug stored in the second chamber to the patient when the cannula accesses the second chamber.


Example 11 is an extension of Example 9 or any other example disclosed herein, wherein the first plunger is positioned adjacent to the second plunger after the first drug is extracted from the first chamber.


Example 12 is an extension of Example 11 or any other example disclosed herein, wherein the drive component is configured to advance the first plunger and the second plunger toward an end of the cartridge, thereby extracting the second liquid drug from the second chamber for delivery to the user through the cannula.


Example 13 is an extension of Example 12 or any other example disclosed herein, wherein the first drug is dispensed over a first amount of time at a first rate and the second drug is dispensed over a second amount of time at a second rate.


Example 14 is an extension of Example 13 or any other example disclosed herein, wherein the first amount of time and the second amount of time are non-overlapping.


Example 15 is an extension of Example 13 or any other example disclosed herein, wherein the first and second rates are different.


Example 16 is an extension of Example 1 or any other example disclosed herein, wherein the first and second plungers are elastomeric plungers.


Example 17 is an extension of Example 1 or any other example disclosed herein, wherein the first and second liquid drugs are different drugs.


Example 18 is an extension of Example 1 or any other example disclosed herein, wherein the first chamber and the second chamber have different volumes.


Example 19 is an extension of Example 1 or any other example disclosed herein, wherein the cartridge comprises glass.


Example 20 is a method, comprising providing a container configured to store a first liquid drug in a first chamber and a second liquid drug in a second chamber, piercing a first plunger with a cannula to couple the cannula to the first liquid drug, driving the first plunger toward an end of the container to extract the first liquid drug from the first chamber through the cannula, piercing a second plunger with the cannula to couple the cannula to the second liquid drug, and driving the first and second plungers toward the end of the container to extract the second liquid drug from the second chamber through the cannula.


Example 21 is an extension of Example 21 or any other example disclosed herein, further comprising piercing the second plunger after substantially all of the first liquid drug is extracted from the first chamber.


Example 22 is an extension of Example 21 or any other example disclosed herein, further comprising piercing the second plunger after a predetermined delay.


Example 23 is an extension of Example 22 or any other example disclosed herein, further comprising extracting the first liquid drug from the first chamber at a first rate and extracting the second liquid drug from the second chamber at a second, different rate.


Example 24 is an extension of Example 23 or any other example disclosed herein, wherein the first and second liquid drugs are different liquid drugs.


Example 25 is an extension of Example 20 or any other example disclosed herein, further comprising sealing the first chamber with the container and the first and second plungers and sealing the second chamber with the container and the second plunger.


Certain embodiments of the present invention were described above. It is, however, expressly noted that the present invention is not limited to those embodiments, but rather the intention is that additions and modifications to what was expressly described herein are also included within the scope of the invention. Moreover, it is to be understood that the features of the various embodiments described herein were not mutually exclusive and can exist in various combinations and permutations, even if such combinations or permutations were not made express herein, without departing from the spirit and scope of the invention. In fact, variations, modifications, and other implementations of what was described herein will occur to those of ordinary skill in the art without departing from the spirit and the scope of the invention. As such, the invention is not to be defined only by the preceding illustrative description.

Claims
  • 1. A multiple stage drug delivery system, comprising: a cartridge;a first plunger positioned in the cartridge;a second plunger positioned in the cartridge, wherein: the first plunger, the second plunger, and the cartridge form a first chamber configured to store a first liquid drug, andthe second plunger and the cartridge form a second chamber configured to store a second liquid drug;a cannula configured to pierce through the first plunger and the second plunger; anda cannula insertion component coupled to the cannula and including one or more springs, the cannula insertion component configured to, in response to being triggered, cause the cannula to pierce the first plunger, wherein: the first plunger is configured to: move toward the second plunger, andexpel the first liquid drug from the first chamber through the cannula in a direction opposite movement of the first plunger toward the second plunger.
  • 2. The multiple stage drug delivery system of claim 1, wherein the cannula is further configured to access the first liquid drug stored in the first chamber after piercing the first plunger.
  • 3. The multiple stage drug delivery system of claim 1, wherein the cannula is coupled to a fluid path that is configured to deliver the first liquid drug stored in the first chamber to a patient when the cannula accesses the first chamber.
  • 4. The multiple stage drug delivery system of claim 1, wherein the first plunger and the second plunger are elastomeric plungers.
  • 5. The multiple stage drug delivery system of claim 1, wherein the first and second liquid drugs are different drugs.
  • 6. The multiple stage drug delivery system of claim 1, wherein the first chamber and the second chamber have different volumes.
  • 7. The multiple stage drug delivery system of claim 1, wherein the cartridge comprises glass.
  • 8. The multiple stage drug delivery system of claim 1, further comprising: a drive component, wherein the drive component: includes one or more springs, different from the one or more springs of the cannula insertion component, andis configured to apply a force to the first plunger that advances the first plunger toward the second plunger, thereby extracting the first liquid drug from the first chamber for delivery to the patient through the cannula.
  • 9. The multiple stage drug delivery system of claim 8, wherein the cannula is configured to pierce the second plunger to access the second liquid drug stored in the second chamber after the first liquid drug is extracted from the first chamber.
  • 10. The multiple stage drug delivery system of claim 9, wherein the cannula couples the second liquid drug stored in the second chamber to the fluid path configured to deliver the second liquid drug to the patient when the cannula accesses the second chamber.
  • 11. The multiple stage drug delivery system of claim 9, wherein the first plunger is positioned adjacent to the second plunger after the first drug is extracted from the first chamber.
  • 12. The multiple stage drug delivery system of claim 8, wherein the drive component is configured to advance the first plunger and the second plunger toward an end of the cartridge, thereby extracting the second liquid drug from the second chamber for delivery to the user through the cannula.
  • 13. The multiple stage drug delivery system of claim 12, wherein the first drug is dispensed over a first amount of time at a first rate and the second drug is dispensed over a second amount of time at a second rate.
  • 14. The multiple stage drug delivery system of claim 13, wherein the first amount of time and the second amount of time are non-overlapping.
  • 15. The multiple stage drug delivery system of claim 13, wherein the first and second rates are different.
  • 16. The multiple stage drug delivery system of claim 8, wherein the drive component is further configured to: apply a force to the first plunger that advances the first plunger toward the second plunger.
  • 17. A method, comprising: providing a container configured to store a first liquid drug in a first chamber and a second liquid drug in a second chamber;actuating a cannula insertion component to apply a force to a cannula to pierce the cannula through a first plunger to couple the cannula to the first liquid drug;driving the first plunger, by applying another force to the first plunger by a drive component coupled to the first plunger, toward an end of the container to extract the first liquid drug from the first chamber through the cannula in a direction opposite to a direction in which the first plunger is being driven;piercing through a second plunger with the cannula to couple the cannula to the second liquid drug; anddriving the first and second plungers together toward the end of the container to extract the second liquid drug from the second chamber through the cannula.
  • 18. The method of claim 17, further comprising piercing the second plunger after substantially all of the first liquid drug is extracted from the first chamber.
  • 19. The method of claim 17, further comprising piercing the second plunger after a predetermined delay.
  • 20. The method of claim 17, further comprising extracting the first liquid drug from the first chamber at a first rate and extracting the second liquid drug from the second chamber at a second, different rate.
  • 21. The method of claim 17, wherein the first liquid drug and second liquid drug are different liquid drugs.
  • 22. The method of claim 17, further comprising sealing the first chamber with the container and the first and second plungers and sealing the second chamber with the container and the second plunger.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/405,489, filed Oct. 7, 2016, which is incorporated herein by reference in its entirety.

US Referenced Citations (185)
Number Name Date Kind
1441508 Marius et al. Jan 1923 A
2198666 Gruskin Apr 1940 A
3176712 Ramsden Apr 1965 A
3297260 Barlow Jan 1967 A
3885662 Schaefer May 1975 A
3946732 Hurscham Mar 1976 A
3993061 O'Leary Nov 1976 A
4108177 Pistor Aug 1978 A
4152098 Moody et al. May 1979 A
4210173 Choksi et al. Jul 1980 A
4221219 Tucker Sep 1980 A
4257324 Stefansson et al. Mar 1981 A
4268150 Chen May 1981 A
4313439 Babb et al. Feb 1982 A
4417889 Choi Nov 1983 A
4424720 Bucchianeri Jan 1984 A
4435173 Siposs et al. Mar 1984 A
4498843 Schneider et al. Feb 1985 A
4507115 Kambara et al. Mar 1985 A
4551134 Slavik et al. Nov 1985 A
4562751 Nason et al. Jan 1986 A
4567549 Lemme Jan 1986 A
4585439 Michel Apr 1986 A
4601707 Albisser et al. Jul 1986 A
4634427 Hannula et al. Jan 1987 A
4671429 Spaanderman et al. Jun 1987 A
4678408 Nason et al. Jul 1987 A
4684368 Kenyon Aug 1987 A
4685903 Cable et al. Aug 1987 A
4755169 Sarnoff et al. Jul 1988 A
4766889 Trick et al. Aug 1988 A
4808161 Kamen Feb 1989 A
4846797 Howson et al. Jul 1989 A
4858619 Toth Aug 1989 A
4898579 Groshong et al. Feb 1990 A
4908017 Howson et al. Mar 1990 A
4944659 Labbe et al. Jul 1990 A
4969874 Michel et al. Nov 1990 A
5007458 Marcus et al. Apr 1991 A
5020325 Henault Jun 1991 A
5062841 Siegel Nov 1991 A
5178609 Ishikawa Jan 1993 A
5205819 Ross et al. Apr 1993 A
5213483 Flaherty et al. May 1993 A
5222362 Maus et al. Jun 1993 A
5236416 McDaniel et al. Aug 1993 A
5261882 Sealfon Nov 1993 A
5261884 Stern et al. Nov 1993 A
5277338 Divall Jan 1994 A
5281202 Weber et al. Jan 1994 A
5346476 Elson Sep 1994 A
5364342 Beuchat et al. Nov 1994 A
5388615 Edlund et al. Feb 1995 A
5433710 VanAntwerp et al. Jul 1995 A
5503628 Fetters et al. Apr 1996 A
5520661 Lal et al. May 1996 A
5533389 Kamen et al. Jul 1996 A
5582593 Hultman Dec 1996 A
5618269 Jacobsen et al. Apr 1997 A
5637095 Nason et al. Jun 1997 A
5665070 McPhee Sep 1997 A
5713875 Tanner, II Feb 1998 A
5747350 Sattler May 1998 A
5748827 Holl et al. May 1998 A
5776103 Kriesel et al. Jul 1998 A
5779676 Kriesel et al. Jul 1998 A
5785688 Joshi et al. Jul 1998 A
5797881 Gadot Aug 1998 A
5800397 Wilson et al. Sep 1998 A
5807075 Jacobsen et al. Sep 1998 A
5839467 Saaski et al. Nov 1998 A
5891097 Saito et al. Apr 1999 A
5897530 Jackson Apr 1999 A
5906597 McPhee May 1999 A
5911716 Rake et al. Jun 1999 A
5919167 Mulhauser et al. Jul 1999 A
5957890 Mann et al. Sep 1999 A
5961492 Kriesel et al. Oct 1999 A
5971963 Choi Oct 1999 A
6019747 McPhee Feb 2000 A
6050457 Arnold et al. Apr 2000 A
6159188 Laibovitz et al. Dec 2000 A
6174300 Kriesel et al. Jan 2001 B1
6190359 Heruth Feb 2001 B1
6200293 Kriesel et al. Mar 2001 B1
6363609 Pickren Apr 2002 B1
6375638 Nason et al. Apr 2002 B2
6474219 Klitmose et al. Nov 2002 B2
6485461 Mason et al. Nov 2002 B1
6485462 Kriesel Nov 2002 B1
6488652 Weijand et al. Dec 2002 B1
6520936 Mann Feb 2003 B1
6527744 Kriesel et al. Mar 2003 B1
6537249 Kriesel et al. Mar 2003 B2
6569115 Barker et al. May 2003 B1
6595956 Gross et al. Jul 2003 B1
6656158 Mahoney et al. Dec 2003 B2
6699218 Flaherty et al. Mar 2004 B2
6723072 Flaherty et al. Apr 2004 B2
6749407 Xie et al. Jun 2004 B2
6851260 Mernoe Feb 2005 B2
6883778 Newton et al. Apr 2005 B1
7018360 Flaherty et al. Mar 2006 B2
7128727 Flaherty et al. Oct 2006 B2
7144384 Gorman et al. Dec 2006 B2
7160272 Eyal et al. Jan 2007 B1
7771392 De Polo et al. Aug 2010 B2
7914499 Gonnelli et al. Mar 2011 B2
8382703 Abdelaal Feb 2013 B1
8499913 Gunter Aug 2013 B2
8939935 O'Connor et al. Jan 2015 B2
9180244 Anderson et al. Nov 2015 B2
9192716 Jugl et al. Nov 2015 B2
9402950 Dilanni et al. Aug 2016 B2
20010016710 Nason et al. Aug 2001 A1
20010056258 Evans Dec 2001 A1
20020029018 Jeffrey Mar 2002 A1
20020032374 Holker et al. Mar 2002 A1
20020037221 Mastrangelo et al. Mar 2002 A1
20020173769 Gray et al. Nov 2002 A1
20020173830 Starkweather et al. Nov 2002 A1
20030040715 D'Antonio et al. Feb 2003 A1
20030097092 Flaherty May 2003 A1
20030109827 Lavi Jun 2003 A1
20030163097 Fleury et al. Aug 2003 A1
20030199825 Flaherty Oct 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040064088 Gorman et al. Apr 2004 A1
20040068224 Couvillon, Jr. et al. Apr 2004 A1
20040069044 Lavi et al. Apr 2004 A1
20040092865 Flaherty et al. May 2004 A1
20040094733 Hower et al. May 2004 A1
20040153032 Garribotto et al. Aug 2004 A1
20050020980 Inoue et al. Jan 2005 A1
20050203461 Flaherty et al. Sep 2005 A1
20050238507 Dilanni et al. Oct 2005 A1
20050273059 Mernoe et al. Dec 2005 A1
20060041229 Garibotto et al. Feb 2006 A1
20060079765 Neer Apr 2006 A1
20060155210 Beckman et al. Jul 2006 A1
20060173439 Thorne, Jr. Aug 2006 A1
20060178633 Garibotto et al. Aug 2006 A1
20060253085 Geismar et al. Nov 2006 A1
20060282290 Flaherty et al. Dec 2006 A1
20070005018 Tekbuchava Jan 2007 A1
20070118405 Campbell et al. May 2007 A1
20070282269 Carter et al. Dec 2007 A1
20080004515 Jennewine Jan 2008 A1
20080051738 Griffin Feb 2008 A1
20080114304 Nalesso et al. May 2008 A1
20080172028 Blomquist Jul 2008 A1
20090024083 Kriesel et al. Jan 2009 A1
20090062767 Van Antwerp et al. Mar 2009 A1
20090198215 Chong et al. Aug 2009 A1
20100036326 Matusch Feb 2010 A1
20100152658 Hanson et al. Jun 2010 A1
20100241066 Hansen et al. Sep 2010 A1
20110054399 Chong et al. Mar 2011 A1
20110144586 Michaud et al. Jun 2011 A1
20110230833 Landman et al. Sep 2011 A1
20120078161 Masterson et al. Mar 2012 A1
20130006213 Arnitz Jan 2013 A1
20130017099 Genoud et al. Jan 2013 A1
20130064701 Konishi Mar 2013 A1
20130245545 Arnold et al. Sep 2013 A1
20130267932 Franke Oct 2013 A1
20140018730 Muller-Pathle Jan 2014 A1
20140127048 Dilanni et al. May 2014 A1
20140128839 Dilanni et al. May 2014 A1
20140142508 Dilanni et al. May 2014 A1
20140148784 Anderson May 2014 A1
20140171901 Langsdorf et al. Jun 2014 A1
20150041498 Kakiuchi et al. Feb 2015 A1
20150057613 Clemente Feb 2015 A1
20150081337 Luce Mar 2015 A1
20150202386 Brady et al. Jul 2015 A1
20150290389 Nessel Oct 2015 A1
20150297825 Focht et al. Oct 2015 A1
20160025544 Kamen et al. Jan 2016 A1
20160193423 Bilton Jul 2016 A1
20170021096 Cole et al. Jan 2017 A1
20170021137 Cole Jan 2017 A1
20170216516 Dale et al. Aug 2017 A1
20170239415 Hwang et al. Aug 2017 A1
20180313346 Oakes et al. Nov 2018 A1
Foreign Referenced Citations (69)
Number Date Country
606281 Oct 1960 CA
1375338 Oct 2002 CN
4200595 Jul 1993 DE
19723648 Aug 1998 DE
0454331 Oct 1991 EP
0789146 Aug 1997 EP
867196 Sep 1998 EP
1065378 Jan 2001 EP
1177802 Feb 2002 EP
1403519 Mar 2004 EP
2397181 Dec 2011 EP
2468338 Jun 2012 EP
2703024 Mar 2014 EP
2830499 Feb 2015 EP
2096275 Feb 1972 FR
2455269 Nov 1980 FR
2507637 Dec 1982 FR
2731475 Sep 1996 FR
357139 Sep 1931 GB
810488 Mar 1959 GB
875034 Aug 1961 GB
1204836 Sep 1970 GB
2008806 Jun 1979 GB
2077367 Dec 1981 GB
2456681 Jul 2009 GB
2549750 Nov 2017 GB
46017 Nov 1977 IL
06063133 Mar 1994 JP
6098988 Apr 1994 JP
H08238324 Sep 1996 JP
2004247271 Sep 2004 JP
2004274719 Sep 2004 JP
2005188355 Jul 2005 JP
2006159228 Jun 2006 JP
2006249130 Sep 2006 JP
1019126 Apr 2003 NL
8101658 Jun 1981 WO
8606796 Nov 1986 WO
9415660 Jul 1994 WO
9855073 Dec 1998 WO
9856293 Dec 1998 WO
9910040 Mar 1999 WO
9910049 Mar 1999 WO
9962576 Dec 1999 WO
0029047 May 2000 WO
0178812 Oct 2001 WO
0220073 Mar 2002 WO
0226282 Apr 2002 WO
02068823 Sep 2002 WO
02076535 Oct 2002 WO
2003097133 Nov 2003 WO
2004056412 Jul 2004 WO
2004110526 Dec 2004 WO
2007066152 Jun 2007 WO
2008133702 Nov 2008 WO
2009039203 Mar 2009 WO
2010139793 Dec 2010 WO
2011075042 Jun 2011 WO
2011133823 Oct 2011 WO
2012073032 Jun 2012 WO
2013050535 Apr 2013 WO
2013137893 Sep 2013 WO
2013149186 Oct 2013 WO
2014149357 Sep 2014 WO
2015032772 Mar 2015 WO
2015117854 Aug 2015 WO
2015167201 Nov 2015 WO
2015177082 Nov 2015 WO
2017187177 Nov 2017 WO
Non-Patent Literature Citations (25)
Entry
International Search Report and Written Opinion for PCT/US2018/014351, dated Jun. 4, 2018, 11 pages.
Lind, et al.,“Linear Motion Miniature Actuators.” Paper presented at the 2nd Tampere International Conference on Machine Automation, Tampere, Finland (Sep. 1998).
Author unknown, “The Animas R-1000 Insulin Pump—Animas Corporation intends to exit the insulin pump business and discontinue the manufacturing and sale of Animas® Vibe® and OneTouch Ping® insulin pumps.” [online], Dec. 1999 [retrieved on Jan. 8, 2019]. Retrieved from the Internet URL: http://www.animaspatientsupport.com/.
Author unknown, CeramTec “Discover the Electro Ceramic Products CeramTec acquired from Morgan Advanced Materials” [online], Mar. 1, 2001 [retrieved on Jan. 8, 2019. Retrieved from the Internet URL: http://www.morgantechnicalceramics.com/.
Vaughan, M.E., “The Design, Fabrication, and Modeling of a Piezoelectric Linear Motor.” Master's thesis, Virginia Polytechnic Institute and State University, VA. (2001).
Galante, et al., “Design, Modeling, and Performance of a High Force Piezoelectric Inchworm Motor,” Journal of Intelligent Material Systems and Structures, vol. 10, 962-972 (1999).
International Search Report and Written Opinion for Interantional application No. PCT/US2017/055054, dated Jan. 25, 2018, 16 pages.
International Search Report and Written Opinion for International application No. PCT/US2018/045155, dated Oct. 15, 2018, 15 pages.
International Preliminary Report on Patentability for International application No. PCT/US2017/034811 dated Nov. 27, 2018 10 pages.
International Search Report and Written Opinion for International application No. PCT/US2017/046508, dated Jan. 17, 2018, 16 pages.
International Search Report and Written Opinion for International application No. PCT/US2017/046777, dated Dec. 13, 2017, 16 pages.
International Search Report and Written Opinion for International application No. PCT/US2017/046737, dated Dec. 14, 2017, 13 pages.
International Search Report and Written Opinion for application No. PCT/US2017/34814, dated Oct. 11, 2017, 16 pages.
International Preliminary Report on Patentability for the International Patent Application PCT/US2018/045155, dated Feb. 13, 2020, 10 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/GB2007/004073, dated Jan. 31, 2008, 8 pages.
European Search Report and Written Opinion for the European Patent Application No. EP19177571, dated Oct. 30, 2019, 10 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2019/035756, dated Jul. 31, 2019, 11 pages.
International Preliminary Report on Patentability for the International Patent Application No. PCT/US18/14351, dated Aug. 1, 2019, 6 pages.
International Preliminary Report on Patentability for the International Patent Application No. PCT/US2017/046777, dated Feb. 28, 2019, 8 pages.
International Preliminary Report on Patentability for the International Patent Application No. PCT/US2017/046737, dated Feb. 28, 2019, 8 pages.
International Preliminary Report on Patentability for the International Patent Application No. PCT/US2017/046508, dated Feb. 21, 2019, 10 pages.
International Preliminary Report on Patentability for the International Patent Application No. PCT/US2017/055054, dated Apr. 18, 2019, 8 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US13/34674, dated Aug. 6, 2013, 19 pages.
EPO Search Report for Application No. 13768938.6, dated Nov. 11, 2015, 7 pages.
International Search Report and Written Opinion for the International Patent Application No. PCT/US2019/063615, dated May 3, 2020, 17 pages.
Related Publications (1)
Number Date Country
20180099100 A1 Apr 2018 US
Provisional Applications (1)
Number Date Country
62405489 Oct 2016 US